Free press releases distribution network?

Agency / Source: Med Services Europe UAB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Licensing Opportunity Available to Pharmaceutical Companies - Med Services Europe has announced that it has obtained rights to out-license a portfolio of prescription pharmaceuticals
Licensing Opportunity Available to Pharmaceutical Companies

 

PRZOOM - /newswire/ - Zurich, Switzerland, 2005/09/09 - Med Services Europe has announced that it has obtained rights to out-license a portfolio of prescription pharmaceuticals.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Med Services Europe GmbH, a “Virtual European Headquarters” for Pharmaceutical and Medical Manufacturers, announced that it has obtained rights to out-license a portfolio of prescription pharmaceuticals.

Dr. Gene Emmer, President of Med Services Europe explained: “We have signed an agreement with a European-based pharmaceutical company that grants us the right to develop a network of distributors for an exciting portfolio of prescription pharmaceutical products. Our client will launch the portfolio in their home market. Med Services Europe will build and manage a network of pharmaceutical companies which will be responsible for marketing, sales and distribution of these products in their home markets. The products in the portfolio offer physicians options for handling Hormone Replacement Therapy (HRT).”

Dr. Emmer explained further about the opportunity that this portfolio presents to pharmaceutical companies “The media has sensationalized the recent findings of the Women’s Health Initiative (WHI) and there has been a strong over-reaction to the study’s findings. This has caused many competitors to abandon this market. However, most physicians agree that HRT is the only effective therapy for climacteric symptoms of menopause, commonly known as hot-flashes, or hot-flush, which can be extremely disabling for a large population of women. The market for HRT products is very large and growing due to ageing of the population and it is hungry for new launches. This portfolio offers many interesting advantages for the market and for the pharmaceutical companies that will represent them”

Dr Emmer encourages pharmaceutical companies to learn more about the opportunity to in-license this portfolio of products. “This is a unique opportunity to obtain marketing rights to an exciting portfolio of products, which are effective for a large and growing market. The media attention to WHI has served to decrease the competitive noise in this market and make this an exciting time for companies coming with a new message.”

Pharmaceutical companies interested in obtaining more information may contact Dr Emmer at Med Services Europe in Switzerland.

About Med Services Europe
Med Services Europe GmbH is located in Zurich Switzerland and specializes in Sales, Marketing and Business Development for Pharmaceutical and Medical manufacturers. Med Services acts as a virtual European Headquarters by developing and managing distribution networks for its clients.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Med Services Europe UAB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Licensing Opportunity Available to Pharmaceutical Companies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dr. Gene Emmer - MedServicesEurope.com 
+41 764249963 info[.]medserviceseurope.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Med Services Europe UAB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Med Services Europe UAB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  1Click Games

Visit  NAKIVO, Inc.

Visit  Intrinsic Executive Search Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today